Selective inhibition of separated forms of human platelet cyclic nucleotide phosphodiesterase by platelet aggregation inhibitors.
D000241:Adenosine / Q000031:analogs & derivatives / Q000494:pharmacology; D001792:Blood Platelets / Q000201:enzymology*; D002110:Caffeine / Q000494:pharmacology; D002848:Chromatography, DEAE-Cellulose; D000242:Cyclic AMP / Q000378:metabolism; D006152:Cyclic GMP / Q000494:pharmacology; D003864:Depression, Chemical; D004176:Dipyridamole / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D007700:Kinetics; D010208:Papaverine / Q000494:pharmacology; D010726:Phosphodiesterase Inhibitors; D010727:Phosphoric Diester Hydrolases / Q000097:blood / Q000302:isolation & purification; D010793:Phthalazines / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects*; D013806:Theophylline / Q000494:pharmacology
D010726:Phosphodiesterase Inhibitors; D010793:Phthalazines; D002110:Caffeine; D004176:Dipyridamole; D013806:Theophylline; D010208:Papaverine; D000242:Cyclic AMP; D010727:Phosphoric Diester Hydrolases; D006152:Cyclic GMP; D000241:Adenosine